Related Experiment Video
Updated: Feb 6, 2026
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
Published on: October 23, 2019
Structural insights into the inhibitor binding and new inhibitor design to Polo-like kinase-1 Polo-box domain using
Maaged Abdullah1, Lalitha Guruprasad1
1a School of Chemistry , University of Hyderabad , Hyderabad , India.
Abstract:
Polo box domain (PBD) from Polo-Like Kinase-1 (PLK-1) a cell cycle regulator is one of the important non-kinase targets implicated in various cancers. The crystal structure of PLK-1 PBD bound to phosphopeptide inhibitor is available and acylthiourea derivatives have been reported as potent PBD inhibitors. In this work, structure and ligand-based pharmacophore methods have been used to identify new PBD inhibitors. The binding of acylthiourea analogs and new inhibitors to PBD were assessed using molecular docking and molecular dynamics simulations to understand their binding interactions, investigate the complex stability and reveal the molecular basis for inhibition. This study provides the binding free energies and residue-wise contributions to decipher the essential interactions in the protein-inhibitor complementarity for complex formation and the design of new PBD inhibitors with better binding. Communicated by Ramaswamy H. Sarma.
Insights
Researchers identified novel Polo-Like Kinase-1 (PLK-1) Polo-box domain (PBD) inhibitors using computational methods. This study elucidates binding interactions and provides insights for developing more effective cancer therapeutics targeting PBD.
Area of Science:
- Biochemistry
- Structural Biology
- Medicinal Chemistry
Background:
- Polo-Like Kinase-1 (PLK-1) is a crucial cell cycle regulator.
- Its Polo-box domain (PBD) is a validated non-kinase target in cancer therapy.
- Acylthiourea derivatives are known potent inhibitors of PLK-1 PBD.
Purpose of the Study:
- To identify novel Polo-box domain (PBD) inhibitors using structure and ligand-based pharmacophore approaches.
- To investigate the binding interactions and stability of inhibitor-PBD complexes.
- To understand the molecular basis for inhibition and guide the design of new PBD inhibitors.
Main Methods:
- Structure and ligand-based pharmacophore modeling.
- Molecular docking and molecular dynamics simulations.
- Binding free energy calculations and residue-wise contribution analysis.
Main Results:
- Identification of new PBD inhibitors with potential therapeutic value.
- Detailed analysis of binding interactions and complex stability.
- Deciphering of key interactions essential for protein-inhibitor complementarity.
Conclusions:
- The study successfully identified novel PBD inhibitors.
- Computational methods provided insights into binding mechanisms and stability.
- Findings facilitate the rational design of improved PBD inhibitors for cancer treatment.
Related Concept Videos
01:52Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:23Dipeptidyl Peptidase 4 Inhibitors
02:54Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
01:25Design Example: Traverse Angle Computations